A ntiphospholipid/cofactor antibodies are detected in only 60% of patients with systemic lupus erythematosus (SLE) with thrombosis. 1 Therefore, we studied thrombophilia factors and their relation with thrombosis in patients with SLE.
METHODS AND RESULTS
Forty eight consecutive patients with SLE were included (39 women, 9 men), 15 with and 33 without past thrombosis (Th and NTh group, respectively). Twenty thrombotic events were identified: 17 deep venous and 1 arterial thrombosis, 2 osteonecrosis. Both groups had comparable clinical, biological, therapeutic data, and mean (SD) SLE disease activity index (SLEDAI) (5 (4.6) v 5.3 (4.8)).
Patients were examined at least one month after thrombosis (>3 months in 11 out of 15). The following parameters were determined: protein C, total and free protein S (in 43 patients because five had antivitamin K treatment), antithrombin, activated protein C resistance (APCR), the R506Q mutation of the factor V gene and the G20210A allele of the prothrombin gene, lupus anticoagulant (LAC) (activated partial thromboplastin time, tissue thromboplastin inhibition test, and platelet neutralisation procedure), IgG anticardiolipin antibodies (aCL), IgG and IgM anti-β 2 -glycoprotein I (anti-β 2 GPI) antibodies, IgG and IgM antiprothrombin antibodies. Homocysteinaemia (fasting and after oral methionine load (100 mg/kg)) was measured in 38 patients (9 Th, 29 NTh patients). Table 1 gives the main results. LAC and aCL >30 GPL units were associated with thrombosis, unlike anti-cofactor antibodies. Anti-β 2 GPI was detected only in positive LAC subjects. Free protein S levels were negatively correlated with the SLEDAI (r=−0.33, p=0.025), and anti-DNA levels (r=−0.31, p=0.04), but not with C reactive protein or ESR. Antiphospholipid/cofactor antibodies were present in 6/8 patients with low free protein S and in 12/35 patients with normal free protein S (p=0.05). One of the two patients with APCR was negative for factor V Leiden. G20210A prothrombin gene mutation was present in one NTh patient. Homocysteinaemia was highly correlated with creatininaemia (r=0.64, p<0.0001), but not with current or cumulative steroid dose (p=0.08).
The patient with arterial thrombosis had neither antiphospholipid/cofactor antibodies nor thrombophilic factor.
DISCUSSION
Our results confirm that LAC and aCL (>30 GPL) are closely associated with thrombosis in SLE. 2 3 Anti-β 2 GPI antibodies do not add any information to LAC, and anti-β 2 GPI and antiprothrombin are not associated with thrombosis. Transiently negative results are unlikely because patients were sampled at least one month after the thrombosis.
As in previous studies, 4 decreased free protein S is common (19%) but not associated with thrombosis. Antiphospholipid/ cofactor antibodies are more prevalent in patients with protein S deficiency, suggesting an autoimmune mechanism that might involve antiprotein S antibodies. 5 The negative correlation between free protein S level and SLE activity suggests a link between disease activity and coagulation activation, 6 7 although we were unable to demonstrate an association between thrombosis and protein S level.
Mild hyperhomocysteinaemia was common (37%) and closely correlated with mild renal function impairment but not with the steroid regimen. 8 9 Hyperhomocysteinaemia is an arterial thrombosis risk factor in SLE, 8 and it was not associated with the mainly venous thrombosis in our sample. Genetic thrombophilia was no more prevalent than in the general population.
Finally, we confirm that LAC and aCL >30 GPL units are the main thrombophilic factors associated with thrombosis in SLE. The role of free protein S and homocysteinaemia remains unclear. Prospective studies, with serial sampling, are needed to elucidate which others factors may play a part. Fifty patients with SLE (48 female; mean age at the time of the examinations 41 years (range 21-76)) and 50 healthy blood donors matched for age and sex with the controls were examined. Genotyping of HLA-DRB1 alleles was carried out with the Dynal RELI SSO HLA-DRB kit, and the DRB1*15/16 subtyping by the method of Ota et al. 2 DQA1 determination was performed by the method of Ota et al. 3 The DQB1 typing was carried out with the INNO-LiPA DQB kit. A χ 2 test with Yates's correction was used for statistical analysis. The significance levels (p<0.05) were adjusted by using Bonferroni's correction to eliminate chance associations (pc value). Odds ratio (OR) values were also calculated.
HLA class II allele polymorphism in Hungarian patients with systemic lupus erythematosus
The main clinical manifestations were articular involvement (92%), anaemia (72%), leucopenia (54%), pericarditis and/or pleuritis (54%), and nephritis (32%).
The DRB1*1501, DRB1*03, and DRB1*07 alleles occurred more frequently in the patients with SLE than in the controls (12/50 (24%) v 3/50 (6%); 20/50 (40%) v 10/50 (20%) and 17/50 (34%) v 6/50 (2%), respectively; ORs 4.4, 2.25, and 3.2, respectively). The DQA1*0102 and *05011 alleles were also more common in the SLE group than in the controls (25/50 (50%) v 13/50 (26%), and 20/50 (40%) v 9/50 (18%), respectively; ORs 2.23 and 2.3, respectively). Of the DQB1 alleles, *0201 and *0602 were detected more frequently in the patients with SLE than in the controls (20/50 (40%) v 8/50 (16%), and 11/50 (22%) v 2/50 (4%), respectively; ORs 2.87 and 6.05, respectively). After the Bonferroni's correction the above mentioned differences did not reach significance.
In contrast, the DRB1*04 and DRB1*11/12 alleles were less common in the patients with SLE than in the controls (3/50 (6%) v 16/50 (32%) and 15/50 (30%) v 25/50 (50%)). The *04 allele was linked with resistance to leucopenia (pc=0.01), the *11/12 alleles with resistance to discoid skin lupus (pc=0.001). The 1106 subtype of the DRB1*11 alleles occurred only in the patients with SLE (4/16 (25%) v 0/25 (0%)).
Connections between the genetic and clinical characteristics were as follows: the DRB1*1501 positivity was less frequent in the patients with than in those without lupus nephritis (LN) (3/16 (19%) v 15/34 (44%)). In contrast, the DRB1*03 and DRB1*07 alleles were more frequent in the patients with than in those without LN (8/16 (50%) v 11/34 (32%) and 7/16 (44%) v 8/34 (24%)). In the patients with pleuritis and/or pericarditis, only the DRB1*07 positivity was more frequent than in the patients without serositis (12/27 (44%) v 3/23 (13%)). The *07 allele was detected more frequently in the patients with one or more severe renal, cardiorespiratory manifestations than in the patients without these potentially fatal features of the disease (16/36 (44%) v 0/14 (0%)). In the patients with anti-SSA and anti-SSB positivity the renal and cerebral involvement was more common, but the differences were not significant (4/8 (50%) v 9/33 (27%) and 2/8 (25%) v 3/33 (9%)).
A comparison with the results of the comprehensive European study showed that agreement was complete for the increased prevalence of the DRB1*1501, DRB1*03, DQA1*0102, DQB1*0201, and DQB1*0602 alleles in the
